Opinion · 1 Dec 2025
Review articlePublished 2017
A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Eleven years after Trastuzumab was approved for use in the treatment of early stage human epidermal growth factor receptor positive breast cancer (HER2+) its clinical benefit has been demonstrated in short and long term follow up studies. The cost-effectiveness of the therapy in this context remains the subject of debate with a wide range of Incremental Cost Effectiveness Ratios (ICERs) reported in the literature. While several reviews of the literature have been undertaken these have not provided a critical analysis of the factors that might underlie this heterogeneity. In this review we provide a critical overview of the literature and discuss potential sources of heterogeneity in reported ICERs. We identify gaps in the current literature and provide a rationale for filling these gaps.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmacoeconomics: Open Access.
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Quynh-Nga Thi Nguyen”
- BylineArticles whose byline prints “Hoa Quoc Nguyen”
- BylineArticles whose byline prints “Ciaran O’Neill”
